CordenPharma: Overview

Full-Service CDMO Partner

  • Formed in 2006 as the pharmaceutical brand of ICIG
  • Full-Service CDMO organized in 6 distinctive platforms with specialized characteristics
  • Marketing & Sales provided by CordenPharma International for separately managed operating companies (legal and financial independence)
  • 8 GMP production facilities in Europe and the United States
  • € 345 million total sales (2015)
  • 1,700 employees

Key Technologies – Drug Substance

  • Small Molecule Intermediates & APIs
  • Excipients
  • Peptides
  • Lipids
  • Carbohydrates
  • Conjugates
  • Highly Potent API’s
  • Oncology API’s
  • Sterile API’s
  • Antibiotics
    • Cephalosporins & Penicillins
    • Monobactams

Key Technologies – Drug Product

  • Injectables (Vials, Ampoules, Pre-filled Syringes)
  • Sterile Emulsion Technology
  • Oral Solid Dosage Forms
  • Coated & Uncoated Tablets
  • Hard Gelatine Capsules
  • Sterile Liquid & Lyophilisation (Vials & Ampules)
  • Primary & Secondary Packaging
  • Blister & Bottle Packaging
  • Serialisation & 2D Data Matrix Coding
  • Clinical Trial Services